Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
More than two dozen people were given the opportunity to confront members of the Sackler family in a virtual environment and share the impactful pain opioid addiction caused their families.
Researchers have now identified 16 new genetic variants associated with severe COVID-19. For that and more research stories, continue reading.
Selecta Biosciences is moving forward with development efforts for its gene therapy program for methylmalonic acidemia after the FDA lifted the hold on its clinical trial on March 9.
Take a look at which states pay the highest and lowest salaries for pharmacists and how that pay compares to the cost of living.
The identification of multiple genomic markers that are linked to specific mental health diseases is beginning to improve treatments and enable precision psychiatry.
AbbVie announced Qulipta hit the mark in its Phase III study by reducing mean monthly migraine days compared to placebo. Learn more about this migraine treatment here.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers
Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.
On Wednesday, Breakthrough Properties announced the launch of StudioLabs, a turnkey, flexible lab and office solution that has been developed for hyper-growth life sciences companies.
The Business Research Company (TBRC), a market research and intelligence firm, released a promising analysis of the global psoriatic arthritis treatment market.
At the Brigham and Women’s Hospital, a male patient with Secondary Progressive Multiple Sclerosis serves as a beacon of hope for those afflicted with the same neurodegenerative disease.
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.